SH3D19 Antibody

What is SH3D19 and why is it important in cellular research?

SH3D19, also known as EBP, EEN-binding protein, EVE1, or Kryn, is a 790 amino acid protein involved in critical cellular signaling pathways. It plays an essential role in regulating ADAM (A disintegrin and metalloproteases) proteins in epidermal growth factor receptor (EGFR)-ligand shedding pathways, which are fundamental for cell signaling and communication . The protein contains five SH3 domains that facilitate protein-protein interactions and may function to suppress Ras-induced cellular transformation and the activation of downstream effectors such as Elk-1 . SH3D19's involvement in these signaling cascades impacts processes including cell growth, differentiation, and migration, making it a significant target for investigations into diseases like cancer, where aberrant signaling can lead to uncontrolled cell proliferation . Additionally, translocation events involving SH3D19 have been implicated in acute myeloid leukemia, suggesting a potential role in carcinogenesis .

What are the available types of SH3D19 antibodies?

There are multiple types of SH3D19 antibodies available for research purposes, varying in host species, clonality, and reactivity profiles. Researchers can choose between:

• Polyclonal antibodies: Such as the rabbit polyclonal antibody (21499-1-AP) from Proteintech, which shows reactivity with human, mouse, and rat samples , or the rabbit polyclonal antibody (PACO36294) from Assay Genie, which demonstrates reactivity with human samples .

• Monoclonal antibodies: Including the mouse monoclonal IgG3 antibody (397.2) from Santa Cruz Biotechnology, which detects SH3D19 in mouse, rat, and human samples , and the mouse monoclonal antibody (5C7) available from other suppliers .

These antibodies come in various forms, including unconjugated preparations for maximum flexibility in experimental design . The diversity in available antibodies allows researchers to select the most appropriate tool based on their specific experimental requirements, target species, and application methods.

What applications are SH3D19 antibodies validated for?

SH3D19 antibodies have been validated for multiple experimental applications, with varying recommended dilutions for optimal results:

It is crucial to note that these applications require specific protocols for optimal results. Many suppliers provide detailed application-specific protocols for their antibodies . Additionally, researchers should be aware that the exact dilution requirements may vary depending on the specific experimental conditions, sample types, and detection methods being used. Therefore, it is recommended that researchers titrate the antibody in each testing system to obtain optimal results .

How do you troubleshoot inconsistent Western blot results with SH3D19 antibodies?

Inconsistent Western blot results when using SH3D19 antibodies can stem from several methodological factors. First, researchers should verify they are detecting the correct band by comparing it with the expected molecular weight. While the calculated molecular weight of SH3D19 is 87 kDa (790 amino acids), the observed molecular weight typically ranges from 45-47 kDa . This discrepancy could be due to post-translational modifications, alternative splicing (as SH3D19 has five known isoforms ), or protein degradation.

For methodological optimization:

• Adjust antibody concentration: If signal is weak, increase concentration gradually from 1:2000 to 1:500 . Conversely, if background is high, dilute further or implement additional blocking steps.

• Optimize sample preparation: Ensure complete protein denaturation and consider using freshly prepared samples, as SH3D19 may be susceptible to degradation during prolonged storage.

• Validate with positive controls: Use cell lines known to express SH3D19, such as HT-1080 or Y79 cells, which have been confirmed to show positive Western blot results .

• Modify blocking conditions: If non-specific binding persists, experiment with different blocking agents (BSA vs. non-fat dry milk) or increase blocking time.

• Consider transfer efficiency: For high molecular weight proteins, extend transfer time or adjust buffer composition to enhance transfer efficiency.

If inconsistencies persist after these optimizations, cross-validate with another SH3D19 antibody that targets a different epitope to confirm the specificity of your observations.

What are the critical factors for achieving specific immunohistochemical detection of SH3D19?

Achieving specific immunohistochemical detection of SH3D19 requires careful attention to several critical factors:

By methodically optimizing these parameters, researchers can achieve consistent and specific immunohistochemical detection of SH3D19 in various tissue samples.

How can researchers effectively distinguish between SH3D19 isoforms in experimental systems?

Distinguishing between the five known isoforms of SH3D19 produced by alternative splicing presents a significant challenge that requires a strategic experimental approach:

• Antibody selection based on epitope mapping: Choose antibodies that target regions either common to all isoforms or specific to particular isoforms. For instance, antibodies targeting the SH3 domains might detect multiple isoforms, while those targeting unique regions could be isoform-specific. Researchers should carefully review the immunogen information; for example, the 21499-1-AP antibody uses an SH3D19 fusion protein (Ag15915) as immunogen , while PACO36294 uses a recombinant Human SH3 domain-containing protein 19 (468-767AA) .

• Western blot analysis with high-resolution gels: Utilize gradient gels or extended run times to achieve better separation of closely sized isoforms. The observed molecular weight of SH3D19 (45-47 kDa) may vary between isoforms, allowing for potential differentiation.

• RT-PCR and qPCR with isoform-specific primers: Design primers that span unique exon junctions to specifically amplify distinct isoforms at the mRNA level, providing quantitative data on isoform expression patterns.

• Mass spectrometry-based proteomics: Employ targeted mass spectrometry to identify unique peptide signatures corresponding to specific isoforms, particularly useful when antibodies cannot distinguish between closely related variants.

• Recombinant expression systems: Generate positive controls by expressing individual isoforms in cell culture systems to establish isoform-specific molecular weight patterns and antibody reactivity profiles.

• Immunoprecipitation followed by isoform-specific detection: Use immunoprecipitation with the available SH3D19 antibodies (such as the 397.2 antibody validated for IP ) followed by methods that can distinguish between isoforms, such as mass spectrometry or high-resolution Western blotting.

By combining these approaches, researchers can develop reliable methods to distinguish between SH3D19 isoforms, enabling more precise studies of their potentially distinct functions in cellular processes.

What cell lines and tissues are most appropriate for studying SH3D19 expression and function?

Based on the available data, researchers should consider the following cell lines and tissues when designing experiments to study SH3D19:

For cell culture models:

• HT-1080 cells (human fibrosarcoma) - Confirmed positive for SH3D19 in Western blot applications

• Y79 cells (human retinoblastoma) - Validated for Western blot detection of SH3D19

• HepG2 cells (human liver cancer) - Validated for immunofluorescence studies of SH3D19

• HeLa cells (human cervical cancer) - Confirmed for immunofluorescence detection of SH3D19

For tissue samples:

• Human kidney tissue - Shows consistently strong SH3D19 expression in immunohistochemistry

• Human heart tissue - Validated for immunohistochemical detection of SH3D19

• Human lung, liver, skeletal muscle, and small intestine - Reported to have high levels of SH3D19 expression

• Human tonsil tissue - Demonstrated positive staining in immunohistochemistry applications

When designing functional studies, researchers should consider that SH3D19 is primarily localized in the cytoplasm but can be recruited to the nucleus by specific interaction partners, such as the MLL-EEN fusion protein . This dynamic localization pattern may be important for understanding the protein's various functions in different cellular compartments.

Additionally, given SH3D19's role in EGFR-ligand shedding pathways , cell models with active EGFR signaling would be particularly valuable for studying its functional significance. Similarly, models relevant to acute myeloid leukemia may be appropriate for investigating SH3D19's potential role in carcinogenesis through translocation events .

How can researchers effectively validate the specificity of SH3D19 antibodies?

Validating antibody specificity is crucial for ensuring reliable research results. For SH3D19 antibodies, researchers should implement a multi-faceted validation approach:

• Genetic knockdown/knockout validation:

  • Perform siRNA knockdown or CRISPR-Cas9 knockout of SH3D19 in relevant cell lines (such as HT-1080 or HepG2 cells )

  • Compare antibody signal in Western blot, IF, or IHC between wild-type and knockdown/knockout samples

  • A genuine SH3D19 antibody should show significantly reduced or eliminated signal in knockdown/knockout samples

• Overexpression validation:

  • Express tagged recombinant SH3D19 in appropriate cell lines

  • Confirm co-localization of antibody signal with tag-specific antibodies in immunofluorescence

  • Verify corresponding increase in signal intensity in Western blot applications

• Peptide competition assay:

  • Pre-incubate the SH3D19 antibody with the immunizing peptide (where available) or recombinant SH3D19

  • Apply to parallel samples alongside untreated antibody

  • Specific antibodies will show diminished or eliminated signal when pre-blocked with antigen

• Cross-validation with multiple antibodies:

  • Compare results using different SH3D19 antibodies targeting distinct epitopes, such as the rabbit polyclonal (21499-1-AP) and mouse monoclonal (397.2)

  • Consistent detection patterns across antibodies increase confidence in specificity

• Mass spectrometry confirmation:

  • Perform immunoprecipitation using the SH3D19 antibody

  • Analyze precipitated proteins by mass spectrometry

  • Confirm the presence of SH3D19 peptides in the immunoprecipitated samples

• Tissue expression pattern alignment:

  • Verify that observed expression patterns in tissues match known SH3D19 distribution (highest in kidney, heart, lung, liver, skeletal muscle, and small intestine)

  • Discrepancies may indicate non-specific binding

By systematically implementing these validation steps, researchers can establish high confidence in the specificity of their SH3D19 antibodies before proceeding with experimental applications.

What are the optimal storage and handling conditions for maintaining SH3D19 antibody activity?

Proper storage and handling of SH3D19 antibodies is critical for maintaining their activity and ensuring reproducible experimental results. Based on manufacturer recommendations, researchers should follow these guidelines:

Storage conditions:

• Temperature: Store SH3D19 antibodies at -20°C for long-term preservation of activity . Avoid repeated freeze-thaw cycles, which can lead to protein denaturation and reduced antibody performance.

• Buffer composition: The optimal storage buffer for many SH3D19 antibodies contains PBS with 0.02% sodium azide and 50% glycerol at pH 7.3 . The glycerol prevents freezing at -20°C and allows for aliquoting without complete thawing.

• Aliquoting: While some manufacturers indicate that aliquoting is unnecessary for -20°C storage , it is generally good practice to divide antibodies into small single-use aliquots to minimize freeze-thaw cycles, particularly for frequently used antibodies.

• Preservatives: Some preparations may contain 0.1% BSA as a stabilizer . Other formulations might contain different preservatives such as Proclin 300 , which helps maintain antibody stability during storage.

Handling recommendations:

• Thawing protocol: Thaw antibodies completely at room temperature or 4°C before use, and mix gently by pipetting or flicking the tube. Avoid vortexing, which can denature antibody proteins.

• Working dilutions: Prepare working dilutions immediately before use and discard any unused diluted antibody. Do not store diluted antibodies for extended periods.

• Sterile technique: Always use sterile technique when handling antibodies to prevent microbial contamination, which can degrade antibody performance.

• Temperature during experiments: During experimental procedures, keep antibodies on ice when not in use to preserve activity.

• Contamination prevention: Use clean pipette tips and tubes to prevent cross-contamination between different antibodies or samples.

By adhering to these storage and handling guidelines, researchers can maximize the lifespan and performance of their SH3D19 antibodies, leading to more consistent and reliable experimental results.

How should researchers interpret discrepancies between predicted and observed molecular weights of SH3D19?

The discrepancy between the calculated molecular weight of SH3D19 (87 kDa, 790 amino acids) and its observed molecular weight in Western blots (45-47 kDa) represents a significant interpretive challenge that researchers must address systematically.

Several biological and technical factors can explain this phenomenon:

• Alternative splicing: SH3D19 is known to have five isoforms produced by alternative splicing . These isoforms may have different molecular weights, potentially explaining the observed bands at 45-47 kDa. Researchers should consult transcript databases to identify which isoforms correspond to which molecular weights.

• Post-translational modifications: Proteolytic processing, phosphorylation, glycosylation, or other modifications can significantly alter the apparent molecular weight of proteins. SH3D19, with its role in signaling pathways , may undergo regulatory modifications that affect its migration pattern in SDS-PAGE.

• Protein structure: Highly charged regions or unusual amino acid compositions can affect SDS binding and protein migration, resulting in aberrant mobility in gels. The presence of five SH3 domains in SH3D19 may contribute to atypical migration patterns.

• Technical considerations: Gel concentration, running buffer composition, and electrophoresis conditions can all impact protein migration. Researchers should standardize these conditions and include appropriate molecular weight markers.

To systematically address these discrepancies, researchers should:

• Use gradient gels to better resolve proteins across a wide molecular weight range

• Perform Western blots with antibodies targeting different epitopes of SH3D19

• Include positive control lysates from cells with confirmed SH3D19 expression (HT-1080 or Y79 cells)

• Consider performing mass spectrometry analysis to definitively identify SH3D19 peptides in bands of interest

• Conduct experiments using recombinant SH3D19 of known molecular weight as a reference standard

By employing these strategies, researchers can more confidently interpret the observed bands and distinguish between genuine SH3D19 detection and potential artifacts or cross-reactivity.

What approaches should be used to quantify SH3D19 expression levels across different experimental conditions?

Accurate quantification of SH3D19 expression levels requires a multi-method approach to ensure reliability and reproducibility across different experimental conditions:

• Western blot densitometry:

  • Use validated SH3D19 antibodies such as 21499-1-AP or 397.2 at optimized dilutions

  • Include appropriate housekeeping protein controls (β-actin, GAPDH, or α-tubulin)

  • Employ standard curves using recombinant SH3D19 for absolute quantification

  • Analyze with validated software (ImageJ, Image Lab, etc.) using appropriate background subtraction

  • Report results as fold-change relative to control conditions or as absolute quantities normalized to total protein

• Quantitative real-time PCR (qRT-PCR):

  • Design primers specific to SH3D19, considering the five known isoforms

  • Validate primer efficiency using standard curves

  • Use multiple reference genes for normalization

  • Employ the 2^(-ΔΔCt) method for relative quantification or absolute quantification with standard curves

  • Correlate mRNA expression with protein levels to assess post-transcriptional regulation

• Immunofluorescence quantification:

  • Use validated antibodies at optimal dilutions (1:10-1:100 for IF/ICC)

  • Maintain consistent acquisition parameters across samples

  • Analyze mean fluorescence intensity in defined cellular compartments (cytoplasm vs. nucleus)

  • Include proper controls for autofluorescence and non-specific binding

  • Consider high-content imaging for automated multi-parameter analysis

• Flow cytometry:

  • Optimize fixation and permeabilization protocols for intracellular SH3D19 detection

  • Use fluorophore-conjugated secondary antibodies with appropriate controls

  • Report data as mean fluorescence intensity (MFI) or positive cell percentage

  • Consider multiparameter analysis to correlate SH3D19 expression with cell cycle or other markers

• ELISA-based quantification:

  • Utilize SH3D19 antibodies validated for ELISA applications at recommended dilutions (1:2000-1:10000)

  • Develop standard curves using recombinant SH3D19

  • Validate assay parameters (sensitivity, specificity, reproducibility)

  • Optimize sample preparation protocols for different tissue/cell types

For all methods, researchers should:

By systematically applying these quantification approaches, researchers can generate reliable data on SH3D19 expression levels across diverse experimental conditions.

How can researchers effectively analyze the interaction between SH3D19 and its binding partners in signaling pathways?

Analyzing the interactions between SH3D19 and its binding partners in signaling pathways requires sophisticated methodological approaches that capture both physical associations and functional consequences:

• Co-immunoprecipitation (Co-IP) strategies:

  • Use SH3D19 antibodies validated for immunoprecipitation, such as the 397.2 mouse monoclonal antibody

  • Optimize lysis conditions to preserve protein-protein interactions while effectively solubilizing membrane-associated complexes

  • Perform reciprocal Co-IPs (pull down with partner protein antibody and detect SH3D19)

  • Include appropriate negative controls (isotype control antibodies, IgG)

  • Consider crosslinking approaches for transient or weak interactions

• Domain-specific interaction mapping:

  • Design experiments targeting the five SH3 domains of SH3D19 individually

  • Create domain deletion or point mutation constructs to identify critical binding regions

  • Use GST-fusion proteins of individual domains in pull-down assays

  • Map binding sites for ADAM proteins and other partners in the EGFR-ligand shedding pathway

• Proximity ligation assay (PLA):

  • Visualize endogenous protein interactions in situ with subcellular resolution

  • Combine antibodies against SH3D19 and putative binding partners

  • Quantify interaction signals in different cellular compartments (cytoplasm vs. nucleus)

  • Analyze how interactions change under different cellular conditions or stimuli

• Mass spectrometry-based interactomics:

  • Perform immunoprecipitation of SH3D19 followed by mass spectrometry (IP-MS)

  • Consider BioID or APEX proximity labeling to capture transient interactions

  • Implement SILAC or TMT labeling for quantitative comparison across conditions

  • Validate novel interactions through orthogonal methods

• Functional readouts of pathway activity:

  • Monitor EGFR-ligand shedding using ELISA or reporter assays

  • Assess the impact of SH3D19 knockdown/overexpression on ADAM protein activity

  • Evaluate downstream signaling (phosphorylation of pathway components) using phospho-specific antibodies

  • Investigate the effect on Ras-induced cellular transformation and Elk-1 activation

• Live-cell imaging approaches:

  • Use fluorescent protein fusions to track SH3D19 and partner proteins

  • Implement FRET or BRET to detect direct protein-protein interactions

  • Analyze protein dynamics during recruitment to the nucleus by MLL-EEN fusion protein

  • Quantify co-localization coefficients under various stimulus conditions

• Computational prediction and validation:

  • Use protein-protein interaction prediction algorithms focusing on SH3 domain recognition motifs

  • Validate predicted interactions experimentally

  • Integrate experimental data into pathway models

By systematically applying these approaches, researchers can develop a comprehensive understanding of SH3D19's role in signaling networks, particularly in the context of EGFR-ligand shedding pathways and potential roles in disease processes such as acute myeloid leukemia .

How can SH3D19 antibodies be utilized in cancer research and potential therapeutic development?

SH3D19 antibodies offer valuable tools for cancer research and therapeutic development based on the protein's implicated roles in signaling pathways and potential involvement in carcinogenesis:

• Diagnostic and prognostic applications:

  • Develop immunohistochemical protocols using validated SH3D19 antibodies (dilution 1:20-1:200) for tumor tissue analysis

  • Correlate SH3D19 expression patterns with clinical outcomes in different cancer types

  • Investigate SH3D19 alterations in acute myeloid leukemia, where SH3D19 translocation events have been implicated

  • Create tissue microarrays to screen SH3D19 expression across multiple tumor samples simultaneously

• Mechanistic studies of cancer signaling:

  • Utilize SH3D19 antibodies to investigate its role in regulating ADAM proteins and EGFR-ligand shedding pathways , which are frequently dysregulated in cancer

  • Examine the function of SH3D19 in suppressing Ras-induced cellular transformation , a critical oncogenic pathway

  • Study how SH3D19 affects downstream effectors such as Elk-1 in different cancer models

  • Investigate interactions between SH3D19 and the MLL-EEN fusion protein in leukemia models

• Drug development and targeted therapy approaches:

  • Use SH3D19 antibodies to screen for compounds that modulate its expression or activity

  • Develop assays to monitor SH3D19-dependent signaling pathways for drug screening

  • Investigate the potential of targeting SH3D19 or its interactions as a therapeutic strategy

  • Evaluate changes in SH3D19 expression or localization in response to existing cancer therapies

• Biomarker development:

  • Validate SH3D19 as a potential biomarker using antibody-based assays in patient samples

  • Develop quantitative ELISA protocols using validated antibodies to measure SH3D19 in patient biofluids

  • Correlate SH3D19 levels with treatment response or disease progression

  • Integrate with other biomarkers for improved diagnostic or prognostic accuracy

• Pre-clinical model development:

  • Generate and characterize genetically engineered mouse models with SH3D19 alterations

  • Use SH3D19 antibodies for phenotypic characterization of these models

  • Validate experimental therapeutics targeting SH3D19-dependent pathways in appropriate models

• Resistance mechanism studies:

  • Investigate alterations in SH3D19 expression or function in therapy-resistant cancer cells

  • Examine how SH3D19-regulated pathways contribute to acquired resistance

  • Develop combination strategies targeting SH3D19-dependent mechanisms alongside conventional therapies

By applying SH3D19 antibodies in these diverse research contexts, investigators can advance understanding of SH3D19's role in cancer biology and potentially develop novel diagnostic approaches or therapeutic interventions targeting this signaling molecule.

What are the emerging techniques for studying SH3D19 localization and dynamics in living cells?

Advanced imaging and molecular techniques are revolutionizing the study of protein localization and dynamics. For SH3D19, which shows dynamic localization between the cytoplasm and nucleus , these emerging approaches offer powerful new insights:

• Live-cell super-resolution microscopy:

  • Implement STORM, PALM, or lattice light-sheet microscopy using fluorescently tagged SH3D19

  • Achieve nanoscale resolution of SH3D19 localization in specific cellular compartments

  • Track the dynamic recruitment of SH3D19 between cytoplasm and nucleus in real-time

  • Visualize co-localization with interaction partners at resolutions below the diffraction limit

• CRISPR-based endogenous tagging:

  • Generate knock-in cell lines expressing fluorescently tagged endogenous SH3D19

  • Avoid artifacts associated with overexpression systems

  • Maintain native regulation and expression levels

  • Enable long-term live imaging of physiologically relevant SH3D19 dynamics

• Optogenetic control systems:

  • Develop light-inducible SH3D19 recruitment or activation systems

  • Control SH3D19 localization with subcellular precision using targeted illumination

  • Study the immediate consequences of SH3D19 relocalization on signaling pathways

  • Create reversible perturbations to examine dynamic signaling processes

• Single-molecule tracking:

  • Label SH3D19 with photoactivatable fluorescent proteins or quantum dots

  • Track individual SH3D19 molecules to determine diffusion coefficients and binding kinetics

  • Identify transient interaction sites and binding partners in living cells

  • Analyze how binding dynamics change in response to cellular stimuli

• FRET/FLIM-based biosensors:

  • Design FRET biosensors to monitor SH3D19 conformational changes

  • Develop sensors that report on SH3D19-partner protein interactions in real-time

  • Use fluorescence lifetime imaging microscopy (FLIM) for quantitative measurements

  • Correlate conformational states with functional outcomes in signaling pathways

• Correlative light and electron microscopy (CLEM):

  • Combine fluorescence imaging of SH3D19 with ultrastructural analysis

  • Precisely localize SH3D19 within cellular ultrastructures

  • Use immune-gold labeling with SH3D19 antibodies for electron microscopy

  • Relate molecular dynamics to cellular architecture

• Advanced fluorescence techniques:

  • Employ fluorescence recovery after photobleaching (FRAP) to measure SH3D19 mobility

  • Use fluorescence correlation spectroscopy (FCS) to analyze diffusion and binding kinetics

  • Implement raster image correlation spectroscopy (RICS) to map SH3D19 dynamics across cellular regions

  • Apply fluorescence lifetime imaging to detect changes in the local environment of SH3D19

These emerging techniques, when combined with validated SH3D19 antibodies or carefully designed fusion proteins, will provide unprecedented insights into the spatiotemporal dynamics of SH3D19 in living cells, particularly its shuttling between cytoplasmic and nuclear compartments and its recruitment to specific signaling complexes.

How might research on SH3D19 contribute to understanding neurodegenerative diseases?

While the current search results primarily focus on SH3D19's roles in cancer and cellular signaling, several properties of this protein suggest potential relevance to neurodegenerative disease research that could be explored using SH3D19 antibodies:

• Protein-protein interaction networks in neurodegeneration:

  • SH3D19 contains five SH3 domains that facilitate protein-protein interactions

  • These domains could potentially interact with proteins implicated in neurodegenerative diseases

  • SH3D19 antibodies could be used to investigate novel protein interactions in neuronal models

  • Immunoprecipitation coupled with mass spectrometry could identify neuron-specific binding partners

• EGFR signaling pathway connections:

  • SH3D19 regulates ADAM proteins in EGFR-ligand shedding pathways

  • EGFR signaling has been implicated in neuroprotection and neuroinflammation

  • Researchers could investigate SH3D19 expression in neuronal tissues using immunohistochemistry (dilution 1:20-1:200)

  • Potential dysregulation of SH3D19-dependent pathways could be explored in neurodegenerative disease models

• Alternative splicing regulation:

  • SH3D19 exists in five isoforms due to alternative splicing

  • Alternative splicing dysregulation is a feature of many neurodegenerative diseases

  • Researchers could develop isoform-specific detection methods using available antibodies

  • Brain region-specific SH3D19 isoform expression patterns could be investigated

• Cytoskeletal regulation and neuronal transport:

  • SH3 domain proteins often interact with cytoskeletal components

  • Neuronal transport defects are common in neurodegenerative diseases

  • Immunofluorescence studies using SH3D19 antibodies (dilution 1:10-1:100) could reveal potential associations with neuronal transport machinery

  • Co-localization with cytoskeletal proteins in neuronal cultures could be assessed

• Stress response pathways:

  • SH3D19's potential role in suppressing Ras signaling suggests involvement in cellular stress responses

  • Cellular stress is a common feature across neurodegenerative diseases

  • Western blot analysis (dilution 1:500-1:2000) could assess SH3D19 expression changes under neurodegenerative stress conditions

  • Manipulation of SH3D19 expression could reveal neuroprotective or neurotoxic effects

• Translocation events and nuclear functions:

  • SH3D19 can be recruited to the nucleus by specific interaction partners

  • Nuclear transport and nuclear function disruptions occur in several neurodegenerative diseases

  • Immunofluorescence with SH3D19 antibodies could track its nuclear localization in neuronal models

  • Changes in SH3D19 localization during neurodegeneration could be investigated

By applying SH3D19 antibodies in neurodegenerative disease research contexts, investigators might uncover previously unrecognized roles for this protein in neuronal function and pathology, potentially opening new avenues for therapeutic intervention.